| Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer. | Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
Wang W, Wang R, Han X, Zhang W, Zhu L, Gu Y., Free PMC Article | 04/16/2024 |
| NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. | NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
Cai C, Tu J, Najarro J, Zhang R, Fan H, Zhang FQ, Li J, Xie Z, Su R, Dong L, Arellano N, Ciboddo M, Elf SE, Gao X, Chen J, Wu R., | 04/8/2024 |
| Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations. | Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N, Kano S, Hatanaka KC, Suzuki T, Hamada S, Idogawa H, Nakamaru Y, Suzuki M, Hatanaka Y, Homma A. | 04/2/2024 |
| miR-196b-5p regulates inflammatory process and migration via targeting Nras in trabecular meshwork cells. | miR-196b-5p regulates inflammatory process and migration via targeting Nras in trabecular meshwork cells.
Zhang J, Yang X, Zong Y, Yu T, Yang X. | 02/27/2024 |
| Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis. | Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis.
Takahashi H, Natsumeda M, Hara N, Koyama A, Shimizu H, Miyashita A, Satake D, Mouri Y, Tsukano J, Kawabe K, Tsukamoto Y, Okada M, Ogura R, Yuki A, Umezu H, Kakita A, Ikeuchi T, Oishi M., Free PMC Article | 02/12/2024 |
| A mutation panel comprising BRAF[V600E], NRAS[Q61R], and NRAS[Q61H] replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients. | A mutation panel comprising BRAF(V600E), NRAS(Q61R), and NRAS(Q61H) replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients.
Eng ZH, Ahmad Jefry MM, Ng KL, Abdul Aziz A, Mat Junit S. | 01/8/2024 |
| Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC). | Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, Girard N, Moro-Sibilot D, Cadranel J, Zalcman G, Ricordel C, Wislez M, Munck C, Poulet C, Gauvain C, Descarpentries C, Wasielewski E, Cortot AB, Baldacci S. | 12/21/2023 |
| BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review. | BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
Valentín-Bravo FJ, Pérez-Rodríguez Á, García-Álvarez C, García-Lagarto E, Saornil-Álvarez MA. | 10/28/2023 |
| Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study. | Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study.
Chang W, Chen Y, Zhou S, Ren L, Xu Y, Zhu D, Tang W, Ye Q, Wang X, Fan J, Wei Y, Xu J., Free PMC Article | 10/24/2023 |
| RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma. | RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma.
Mustansar T, Mirza T, Hussain M. | 09/12/2023 |
| Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania. | Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA, Marinca MV, Gafton B, Alexa-Stratulat T, Rusu A, Froicu EM, Sur D, Lungulescu CV, Popovici L, Lefter AV, Afrăsânie I, Ivanov AV, Miron L, Rusu C., Free PMC Article | 08/30/2023 |
| RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. | RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
Ren JG, Xing B, Lv K, O'Keefe RA, Wu M, Wang R, Bauer KM, Ghazaryan A, Burslem GM, Zhang J, O'Connell RM, Pillai V, Hexner EO, Philips MR, Tong W., Free PMC Article | 08/28/2023 |
| Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series. | Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
Mahdi Y, Khmou M, Souadka A, Agouri HE, Ech-Charif S, Mounjid C, Khannoussi BE., Free PMC Article | 06/13/2023 |
| Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer. | Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer.
Paula Simedan Vila A, Helena Rodrigues G, Leite Marzochi L, Garcia de Oliveira-Cucolo J, Lívia Silva Galbiatti-Dias A, Felipe Maciel Andrade R, de Santi Neto D, Gomes Netinho J, Castiglioni L, Cristina Pavarino É, Maria Goloni-Bertollo E. | 05/19/2023 |
| MicroRNA-708 emerges as a potential candidate to target undruggable NRAS. | MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM, Chien PC, Kao MC, Chiu PY, Chen PX, Hsu YL, Liu C, Liang X, Lin KT., Free PMC Article | 05/8/2023 |
| Analysis of a pre-2017 follicular variant papillary thyroid carcinoma cohort reclassified as noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP): an 11-year retrospective single institution experience. | Analysis of a pre-2017 follicular variant papillary thyroid carcinoma cohort reclassified as noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP): an 11-year retrospective single institution experience.
Beg S, Khan SI, Cui I, Scognamiglio T, Rao R. | 03/24/2023 |
| Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients. | Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
Durinikova A, Folta A, Pardy F, Svaton J, Drncova M, Weinbergerova B, Cetkovsky P, Racil Z, Jindra P, Szotkowski T, Zak P, Mayer J, Jeziskova I. | 03/5/2023 |
| RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update. | RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.
Ooi ZS, Pang SW, Teow SY. | 01/14/2023 |
| NRAS p.Q61R/K allele load is correlated to different phenotypes of congenital melanocytic naevi. | NRAS p.Q61R/K allele load is correlated to different phenotypes of congenital melanocytic naevi.
Zhao X, Dai Y, Zhang L, Liu Y, Chen H, Yue X, Yu L. | 12/3/2022 |
| Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. | Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
Zheng ZY, Elsarraj H, Lei JT, Hong Y, Anurag M, Feng L, Kennedy H, Shen Y, Lo F, Zhao Z, Zhang B, Zhang XH, Tawfik OW, Behbod F, Chang EC., Free PMC Article | 10/29/2022 |
| NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. | NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H, Zhang Q, Duan Q, Tan Y, Sun T, Qi C., Free PMC Article | 09/3/2022 |
| Genomic landscape of lymphatic malformations: a case series and response to the PI3Kalpha inhibitor alpelisib in an N-of-1 clinical trial. | Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial.
Shaheen MF, Tse JY, Sokol ES, Masterson M, Bansal P, Rabinowitz I, Tarleton CA, Dobroff AS, Smith TL, Bocklage TJ, Mannakee BK, Gutenkunst RN, Bischoff J, Ness SA, Riedlinger GM, Groisberg R, Pasqualini R, Ganesan S, Arap W., Free PMC Article | 07/16/2022 |
| NRAS(Q61R) mutation in human endothelial cells causes vascular malformations. | NRAS(Q61R) mutation in human endothelial cells causes vascular malformations.
Boscolo E, Pastura P, Schrenk S, Goines J, Kang R, Pillis D, Malik P, Le Cras TD., Free PMC Article | 07/9/2022 |
| Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. | Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
Baba O, Bidikian A, Mukherji D, Shamseddin A, Temraz S, Fakhruddin N, Khazzouh M, Ghizzawi D, Abdel Khalek R, Zaatari G, Mahfouz R. | 06/25/2022 |
| Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family. | Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family.
Brown KM, Xu M, Sargen M, Jang H, Zhang M, Zhang T, Zhu B, Jones K, Kim J, Mendoza L, Hayward NK, Tucker MA, Goldstein AM, Yang XR, Stewart DR, Hicks B, Consonni D, Pesatori AC, Fargnoli MC, Peris K, Stratigos A, Menin C, Ghiorzo P, Puig S, Nagore E, MelaNostrum Consortium, Andresson T, Nussinov R, Calista D, Landi MT., Free PMC Article | 06/25/2022 |